Expression of cyclooxygenase-2 and microsomal prostagalandin E synthase-1 in head and neck squamous cell carcinoma

Kawata, Ryo; Hyo, Sawako; Araki, Michitoshi; Takenaka, Hiroshi

doi:10.1016/j.anl.2009.11.009

Cited by 13 publications

(11 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This result was in agreement with result of Kawata and Pandy. 8,9 Kawata showed that expression of COX2 in welldifferentiated head and neck SCC was stronger than poorly differentiated SCC. 8 Kyzas showed a relation between COX2 expression and lymph node metastases at the time of diagnosis.…”

Section: Discussionmentioning

confidence: 99%

“…8,9 Kawata showed that expression of COX2 in welldifferentiated head and neck SCC was stronger than poorly differentiated SCC. 8 Kyzas showed a relation between COX2 expression and lymph node metastases at the time of diagnosis. He also showed a correlation between COX2-E and clinical stage, but no correlation was observed between COX2-E and histologic grade.…”

Section: Discussionmentioning

confidence: 99%

“…6,7 COX2 can increase prostaglandin synthesis in many malignant cells including esophagus, colon, lung and prostate. [7][8][9] This increase can drive tumor extention by angiogenesis and cell proliferation, modulating inflammatory and immune responses and inhibiting apoptosis. 7,[9][10][11][12] Lio et al showed that aspirin reduced the in vitro and in vivo proliferation of esophageal cancer cells and induced apoptosis , in a dose dependent manner.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Comparison of COX2 Expression between Oral Squamous Cell Carcinoma, Leukoplakia and Normal Mucosa

Amirchaghmaghi

Mohtasham²,

Mozaffari³

2012

The Journal of Contemporary Dental Practice

View full text Add to dashboard Cite

Aim:To compare cyclooxygenase 2 expression (COX2-E) between normal, oral leukoplakia lesions and different grades of oral squamous cell carcinoma (SCC). Materials and methods:Around 90 paraffin embedded blocks consisting of 45 SCC, 15 leukoplakia and 17 controls were selected for immunohistochemistry (IHC) for detection of COX2-E. COX2-E was divided in four grades, as A (0-10%), B (11-40%), C (41-70%) and D (> 70%) cellularity.Results: Mean age of the patients was 55.17 ± 18.41

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Comparison of COX2 Expression between Oral Squamous Cell Carcinoma, Leukoplakia and Normal Mucosa

Amirchaghmaghi

Mohtasham²,

Mozaffari³

2012

The Journal of Contemporary Dental Practice

View full text Add to dashboard Cite

show abstract

“…COX-2 and mPGES-1 have been shown to be co-expressed in OSCC (81), and their expression was positively associated with proliferation and differentiation (82). In OSCC patients who had not received chemotherapy before surgery, high levels of COX-2 and mPGES-1 were associated with poor prognosis (83).…”

Section: Prostaglandin E 2 Synthase Enzymes (Mpges-1 Mpges-2 and Cpges)mentioning

confidence: 99%

Intersecting Mechanisms of Hypoxia and Prostaglandin E2-Mediated Inflammation in the Comparative Biology of Oral Squamous Cell Carcinoma

Nasry

Martin

2021

Front. Oncol.

View full text Add to dashboard Cite

The importance of inflammation in the pathogenesis of cancer was first proposed by Rudolph Virchow over 150 years ago, and our understanding of its significance has grown over decades of biomedical research. The arachidonic acid pathway of inflammation, including cyclooxygenase (COX) enzymes, PGE2 synthase enzymes, prostaglandin E2 (PGE2) and PGE2 receptors has been extensively studied and has been associated with different diseases and different types of cancers, including oral squamous cell carcinoma (OSCC). In addition to inflammation in the tumour microenvironment, low oxygen levels (hypoxia) within tumours have also been shown to contribute to tumour progression. Understandably, most of our OSCC knowledge comes from study of this aggressive cancer in human patients and in experimental rodent models. However, domestic animals develop OSCC spontaneously and this is an important, and difficult to treat, form of cancer in veterinary medicine. The primary goal of this review article is to explore the available evidence regarding interaction between hypoxia and the arachidonic acid pathway of inflammation during malignant behaviour of OSCC. Overlapping mechanisms in hypoxia and inflammation can contribute to tumour growth, angiogenesis, and, importantly, resistance to therapy. The benefits and controversies of anti-inflammatory and anti-angiogenic therapies for human and animal OSCC patients will be discussed, including conventional pharmaceutical agents as well as natural products.

show abstract

“…Table 2 summarizes the cancers in which mPGES-1 expression has been shown to be increased compared with normal tissues. mPGES-1 is overexpressed in gastrointestinal (GI) cancers (including esophageal [34], gastric [35–38], colorectal [39,40], liver [41,42] and pancreatic cancers [43]), brain cancers (gliomas and medulloblastomas [44,45]), breast cancer [46], kidney cancer [47], thyroid cancer [48] and several cancers derived from the epithelium (including head and neck [49,50], penis [51], lungs [52–54], larynx [55], cervix [56], endometrium [57] and ovary [58]). In a recent review by Nakanishi et al , we summarized the role of mPGES-1 in colon carcinogenesis, where data appear to be somewhat contradictory in knockout mice [59].…”

Section: Role Of Mpges-1 In Diseasesmentioning

confidence: 99%

Identification and Development of Mpges-1 Inhibitors: Where We are At?

Chang

Meuillet²

2011

Future Med. Chem.

View full text Add to dashboard Cite

Microsomal prostaglandin E synthase-1 (mPGES-1) is the terminal synthase responsible for the synthesis of the pro-tumorigenic prostaglandin E2 (PGE2). mPGES-1 is overexpressed in a wide variety of cancers. Since its discovery in 1997 by Bengt Samuelsson and collaborators, the enzyme has been the object of over 200 peer-reviewed articles. Although today mPGES-1 is considered a validated and promising therapeutic target for anticancer drug discovery, challenges in inhibitor design and selectivity are such that up to this date there are only a few published records of small-molecule inhibitors targeting the enzyme and exhibiting some in vivo anticancer activity. This review summarizes the structures, and the in vitro and in vivo activities of these novel mPGES-1 inhibitors. Challenges that have been encountered are also discussed.

show abstract

Expression of cyclooxygenase-2 and microsomal prostagalandin E synthase-1 in head and neck squamous cell carcinoma

Cited by 13 publications

References 15 publications

Comparison of COX2 Expression between Oral Squamous Cell Carcinoma, Leukoplakia and Normal Mucosa

Comparison of COX2 Expression between Oral Squamous Cell Carcinoma, Leukoplakia and Normal Mucosa

Intersecting Mechanisms of Hypoxia and Prostaglandin E2-Mediated Inflammation in the Comparative Biology of Oral Squamous Cell Carcinoma

Identification and Development of Mpges-1 Inhibitors: Where We are At?

Contact Info

Product

Resources

About